Skip to Content

Felodipine Pregnancy and Breastfeeding Warnings

Felodipine is also known as: Plendil

Medically reviewed on December 15, 2017.

Felodipine Pregnancy Warnings

A retrospective review of 78 women with first-trimester exposure to calcium channel blockers (CCBs) (1% or 1 was taking felodipine) revealed no increase in major malformations compared with a control group matched for maternal age and smoking. This review suggests that CCBs do no represent a major teratogenic risk.

Felodipine has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of digital anomalies in rabbits treated with felodipine when high doses were given. There are no controlled data in human pregnancy. Felodipine should only be given during pregnancy when benefit outweighs risk to the fetus.

See references

Felodipine Breastfeeding Warnings

There are no data on the excretion of felodipine into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.
  2. Casele HL, Windley KC, Prieto JA, Gratton R, Laifer SA "Felodipine use in pregnancy: Report of three cases." J Reprod Med 42 (1997): 378-81
  3. Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover E, Cook L, Mcelhatton PR, Schmidt MA, Koren G "The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study." Am J Obstet Gynecol 174 (1996): 823-8

References for breastfeeding information

  1. "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.